Chemistry:HBL20016

From HandWiki

HBL20016, also known as 5-methylthio-6-fluoro-N,N-dimethyltryptamine (5-MeS-6-F-DMT), is a non-selective serotonin receptor agonist and serotonergic psychedelic of the tryptamine family related to 5-MeO-DMT.[1][2] It is the 6-fluoro derivative of 5-MeS-DMT and the 5-methylthio derivative of 6-fluoro-DMT.[2]

The drug acts as an agonist of the serotonin 5-HT1A, 5-HT2A, 5-HT2B, and 5-HT2C receptors.[1][2] Its activational potencies (EC50) are 645 nM for the serotonin 5-HT1A receptor, 1.64 nM for the serotonin 5-HT2A receptor, 3.42 nM for the serotonin 5-HT2B receptor, and 8.37 nM for the serotonin 5-HT2C receptor.[1][2] HBL20016 produces the head-twitch response (HTR), a behavioral proxy of psychedelic effects, in rodents, and hence would be expected to be hallucinogenic in humans.[1][2] The HTR induced by HBL20016 is comparable in magnitude to that occurring with psilocybin.[2] HBL20016 has shown antiobsessional-like effects in rodents, for instance against obsessive self-grooming.[1][2]

The chemical synthesis of HBL20016 has been described.[2]

HBL20016 was first described in the scientific literature in December 2024.[1][2] It was developed by Negev Labs and Parow Entheobiosciences.[1] A related drug, HBL20017 (4-F-5-MeS-DMT), which is a non-hallucinogenic agent with an otherwise mostly similar pharmacological profile, is under investigation for the potential treatment of obsessive–compulsive disorder (OCD).[1][2]

See also

References

  1. 1.0 1.1 1.2 1.3 1.4 1.5 1.6 1.7 "ACNP 63rd Annual Meeting: Poster Abstracts P609-P914: P660. A Novel, Non-Hallucinogenic Psychedelic for the Treatment of Obsessive-Compulsive Disorder". Neuropsychopharmacology 49 (Suppl 1): 418–594 (448–449). December 2024. doi:10.1038/s41386-024-02013-y. PMID 39643635. 
  2. 2.00 2.01 2.02 2.03 2.04 2.05 2.06 2.07 2.08 2.09 "Compounds and uses thereof as modulators of serotonin receptors". 10 April 2025. https://patents.google.com/patent/WO2025220005A1/en.